AMBEV S.A. current report, Q3 FY2022

Business Context and Reporting Period

This Form 6-K filing by AMBEV S.A. covers the period from August 1, 2022, to August 31, 2022. The report discloses consolidated transactions of securities and derivatives involving the company's Board of Directors, Management, and Fiscal Council in compliance with Article 11 of CVM Instruction # 358/2002.

Key Financial Metrics

The filing text does not provide corporate financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document exclusively details insider trading activity.

Group Initial Balance (Shares/ADRs) Transactions (Net) Final Balance (Shares/ADRs)
Board of Directors 12,194,947 Common Shares None 12,194,947 Common Shares
Management 2,328,292 Common Shares; 541,613 ADRs Sold 167,721 Common Shares; Sold 94,178 ADRs 2,160,571 Common Shares; 447,435 ADRs
Fiscal Council 0 None 0

Material Changes

Material changes are limited to the reduction in equity holdings by the Management group during August 2022:

  • Common Shares: Decreased from 2,328,292 to 2,160,571 (a net reduction of 167,721 shares).
  • ADRs: Decreased from 541,613 to 447,435 (a net reduction of 94,178 ADRs).
  • Transaction Volume: Management sold securities through intermediaries including XP Investments, HSBC Securities, Itaú Corretora, and XP Corretora. Total reported volume for ADR sales was approximately R$ 1,460,114.74, and Common Share sales totaled approximately R$ 2,536,432.90.

No transactions were reported for the Board of Directors or the Fiscal Council.

Guidance, Outlook, and Risks

The filing text does not provide guidance, outlook, management commentary on operations, risks, contingencies, or unusual items. The document is strictly a regulatory disclosure of insider trading activity.

Investor Verification Checklist

  • Verify the total volume of shares sold by Management against the company's overall float to assess market impact.
  • Confirm the specific dates of sales (August 3, 4, 8, 11, 12, 15, 16, 18, 29) against the stock price performance during that period.
  • Note that the Board of Directors held a static position of over 12 million shares with no trading activity.
  • Ensure the distinction between Common Shares and ADRs is maintained when calculating total equity exposure for the Management group.